Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for neurological, endocrine, and psychiatric disorders in the United States. Its primary products include INGREZZA, a treatment for tardive dyskinesia, and ORILISSA, used for endometriosis. The company is advancing several clinical candidates, including elagolix, which targets uterine fibroids, and opicapone, an adjunct therapy for Parkinson’s disease. Additionally, Neurocrine is developing innovative therapies such as NBI-74788 for congenital adrenal hyperplasia and NBIb-1817, a gene replacement therapy for Parkinson’s disease. The company’s research also encompasses treatments for various conditions, including anxiety, depression, and epilepsy. Neurocrine has established collaborations with multiple pharmaceutical companies to enhance its research and development capabilities. Founded in 1992, the company is headquartered in San Diego, California.
Xenon Pharmaceuticals is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits or phenotypes. They apply their expertise to predict which phenotypes are caused by single-gene defects. By identifying and characterizing the single-gene defects responsible for such severe phenotypes, they gain valuable insights into their function in human biology and their potential as drug targets. Given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, they are developing proprietary product candidates to treat both orphans as well as more prevalent diseases
Northwest Neurologic
Acquisition in 1998
Northwest Neurologic Inc. (NNL) identifies and discovers neuroendocrine pathways to control obesity, stroke, depression, and other medical problems.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.